Guangdong Provincial People's Hospital
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1946-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
202
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (138 trials with phase data)• Click on a phase to view related trials
A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure
- Conditions
- Hemodialysis ComplicationHeart Failure
- Interventions
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT07047547
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)
- Conditions
- Cardiovascular Diseases (CVD)Depression Anxiety Disorder
- Interventions
- Behavioral: Moderate-intensity continuous movement and Antipsychotics interventionDrug: Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine)
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 106
- Registration Number
- NCT07025590
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
- Conditions
- NSCLC (Non-small Cell Lung Cancer)
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT07016126
- Locations
- 🇨🇳
Guangdong provincial people's hospital, Guangzhou, Guangdong, China
Safety and Efficacy of Exercise in Type-B Aortic Dissection
- Conditions
- Type B Aortic Dissection
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07009067
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Investigation Into the Safety and Efficacy of ICG-Labeled Fluorescence Imaging Technology in Guiding the Resection of Bone and Soft Tissue Tumors
- Conditions
- Bone NeoplasmsSoft Tissue Neoplasms
- Interventions
- Drug: Indocyanine green (ICG)
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06979115
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 41
- Next
News
Henlius Presents Comprehensive Serplulimab Data at ASCO 2025, Demonstrating Broad Efficacy Across Multiple Cancer Types
Shanghai Henlius Biotech presented results from over ten studies of serplulimab (HANSIZHUANG) at the 2025 ASCO Annual Meeting, covering lung and gastrointestinal cancers with promising efficacy data.
Breakthrough Diagnostic Tools for Early Fatty Liver Disease Detection: AI and Blood Tests Show Promise
New AI technology developed at University of Washington has identified hundreds of undiagnosed fatty liver disease cases by analyzing existing imaging scans, with 83% of patients with evidence of the disease lacking formal diagnosis.